Literature DB >> 15685521

Isolated sarcoid granulomatous interstitial nephritis responding to infliximab therapy.

Julia Thumfart1, Dominik Müller, Birgit Rudolph, Miriam Zimmering, Uwe Querfeld, Dieter Haffner.   

Abstract

Sarcoidosis is a systemic disease with multiorgan involvement. In children, renal impairment of sarcoidosis usually is caused by either hypercalcemia leading to nephrocalcinosis or interstitial nephritis with or without granulomata. We report the case of a 13-year-old boy presenting with severe arterial hypertension and acute renal failure caused by an isolated sarcoid granulomatous interstitial nephritis (GIN). Other known causes of GIN, eg, drug intake or fungal or mycobacterial infection, were excluded, and there was no evidence of extrarenal sarcoid involvement. Renal function improved initially with prednisone treatment. Blood pressure was controlled using ramipril, nifedipine, furosemide, dihydralazine, and metoprolol. Later, the patient showed signs of severe steroid toxicity and progressive renal failure. Monthly treatment with infliximab, a tumor necrosis factor-alpha antibody, was started, resulting in steady improvement in renal function and resolution of renal granulomata. In addition, antihypertensive medication could be reduced, and low-dose prednisone therapy was maintained. To our knowledge, this is the first report of successful treatment with infliximab of a patient with sarcoid GIN.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15685521     DOI: 10.1053/j.ajkd.2004.10.011

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  15 in total

1.  Successful steroid-sparing treatment of renal limited sarcoidosis with mycophenolate mofetil.

Authors:  Asha Moudgil; Ronald M Przygodzki; Kanwal K Kher
Journal:  Pediatr Nephrol       Date:  2005-12-17       Impact factor: 3.714

2.  Infliximab therapy for hepatic and intestinal sarcoidosis.

Authors:  Helen S Te; Lucas Campbell; Saima Chohan
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-06

3.  A curious case of growth failure and hypercalcemia: Answers.

Authors:  Mallory L Downie; Jaap Mulder; Rayfel Schneider; Lillian Lim; Nasrin Tehrani; Jonathan D Wasserman; Shai Fuchs; Rohan John; Damien G Noone; Diane Hebert
Journal:  Pediatr Nephrol       Date:  2017-08-07       Impact factor: 3.714

4.  Treatment of therapy-resistant sarcoidosis with adalimumab.

Authors:  José Luis Callejas-Rubio; Norberto Ortego-Centeno; Lourdes Lopez-Perez; Maria Nicolas Benticuaga
Journal:  Clin Rheumatol       Date:  2005-10-25       Impact factor: 2.980

5.  Isolated renal relapse of sarcoidosis under low-dose glucocorticoid therapy.

Authors:  Christof Mayer; Angela Müller; Jan Halbritter; Hubert Wirtz; Michael Stumvoll
Journal:  J Gen Intern Med       Date:  2008-04-18       Impact factor: 5.128

6.  Mizoribine for renal sarcoidosis: effective steroid tapering and prevention of recurrence.

Authors:  Shuichi Ito; Tomonori Harada; Tomoko Nakamura; Tomoyuki Imagawa; Kiyotaka Nagahama; Takeshi Sasaki; Shuichiro Fujinaga; Yukoh Aihara; Shumpei Yokota
Journal:  Pediatr Nephrol       Date:  2008-09-13       Impact factor: 3.714

7.  Sarcoidosis presenting with hearing loss and granulomatous interstitial nephritis in an adolescent.

Authors:  Michelle N Rheault; Juan C Manivel; Samuel C Levine; Alan R Sinaiko
Journal:  Pediatr Nephrol       Date:  2006-06-30       Impact factor: 3.651

8.  Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis.

Authors:  José Luis Callejas-Rubio; Lourdes López-Pérez; Norberto Ortego-Centeno
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

9.  Childhood sarcoidosis: A rare but fascinating disorder.

Authors:  Avinash K Shetty; Abraham Gedalia
Journal:  Pediatr Rheumatol Online J       Date:  2008-09-23       Impact factor: 3.054

10.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.

Authors:  Julie R Brahmer; Hamzah Abu-Sbeih; Paolo Antonio Ascierto; Jill Brufsky; Laura C Cappelli; Frank B Cortazar; David E Gerber; Lamya Hamad; Eric Hansen; Douglas B Johnson; Mario E Lacouture; Gregory A Masters; Jarushka Naidoo; Michele Nanni; Miguel-Angel Perales; Igor Puzanov; Bianca D Santomasso; Satish P Shanbhag; Rajeev Sharma; Dimitra Skondra; Jeffrey A Sosman; Michelle Turner; Marc S Ernstoff
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.